RU2019114035A - ВАРИАНТЫ ХОМИНГ-ЭНДОНУКЛЕАЗЫ ТКРα - Google Patents
ВАРИАНТЫ ХОМИНГ-ЭНДОНУКЛЕАЗЫ ТКРα Download PDFInfo
- Publication number
- RU2019114035A RU2019114035A RU2019114035A RU2019114035A RU2019114035A RU 2019114035 A RU2019114035 A RU 2019114035A RU 2019114035 A RU2019114035 A RU 2019114035A RU 2019114035 A RU2019114035 A RU 2019114035A RU 2019114035 A RU2019114035 A RU 2019114035A
- Authority
- RU
- Russia
- Prior art keywords
- polypeptide
- cell
- biologically active
- active fragment
- paragraphs
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 44
- 229920001184 polypeptide Polymers 0.000 claims 42
- 102000004196 processed proteins & peptides Human genes 0.000 claims 42
- 210000004027 cell Anatomy 0.000 claims 20
- 239000012634 fragment Substances 0.000 claims 19
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 230000004568 DNA-binding Effects 0.000 claims 8
- 102000004190 Enzymes Human genes 0.000 claims 7
- 108090000790 Enzymes Proteins 0.000 claims 7
- 108091033319 polynucleotide Proteins 0.000 claims 7
- 102000040430 polynucleotide Human genes 0.000 claims 7
- 239000002157 polynucleotide Substances 0.000 claims 7
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 3
- 102000004533 Endonucleases Human genes 0.000 claims 3
- 108010042407 Endonucleases Proteins 0.000 claims 3
- 108060002716 Exonuclease Proteins 0.000 claims 3
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 3
- 102000013165 exonuclease Human genes 0.000 claims 3
- 239000011701 zinc Substances 0.000 claims 3
- 229910052725 zinc Inorganic materials 0.000 claims 3
- 102220485790 Destrin_S40R_mutation Human genes 0.000 claims 2
- 102220491802 High mobility group protein B1_S35E_mutation Human genes 0.000 claims 2
- 102220553625 Lens fiber major intrinsic protein_E42S_mutation Human genes 0.000 claims 2
- 108091008874 T cell receptors Proteins 0.000 claims 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 2
- 102220559237 Voltage-dependent L-type calcium channel subunit alpha-1C_N32R_mutation Human genes 0.000 claims 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 2
- 102220481234 eIF5-mimic protein 2_R28D_mutation Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102200104655 rs11555566 Human genes 0.000 claims 2
- 102200131539 rs121912431 Human genes 0.000 claims 2
- 102200131563 rs121912455 Human genes 0.000 claims 2
- 102200081901 rs137854510 Human genes 0.000 claims 2
- 102220040900 rs587778522 Human genes 0.000 claims 2
- 102220085953 rs864622049 Human genes 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims 2
- 206010003445 Ascites Diseases 0.000 claims 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims 1
- 108060004795 Methyltransferase Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000002151 Pleural effusion Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000004700 fetal blood Anatomy 0.000 claims 1
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 1
- 239000012642 immune effector Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 210000001165 lymph node Anatomy 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 210000000581 natural killer T-cell Anatomy 0.000 claims 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 claims 1
- 210000001541 thymus gland Anatomy 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/11—Exodeoxyribonucleases producing 5'-phosphomonoesters (3.1.11)
- C12Y301/11002—Exodeoxyribonuclease III (3.1.11.2)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Television Signal Processing For Recording (AREA)
- Treating Waste Gases (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662406689P | 2016-10-11 | 2016-10-11 | |
| US62/406,689 | 2016-10-11 | ||
| US201662414266P | 2016-10-28 | 2016-10-28 | |
| US62/414,266 | 2016-10-28 | ||
| PCT/US2017/056178 WO2018071565A1 (en) | 2016-10-11 | 2017-10-11 | TCRa HOMING ENDONUCLEASE VARIANTS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2019114035A true RU2019114035A (ru) | 2020-11-13 |
Family
ID=61905974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019114035A RU2019114035A (ru) | 2016-10-11 | 2017-10-11 | ВАРИАНТЫ ХОМИНГ-ЭНДОНУКЛЕАЗЫ ТКРα |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11591582B2 (enExample) |
| EP (1) | EP3534916A4 (enExample) |
| JP (1) | JP7104710B2 (enExample) |
| KR (1) | KR20190065382A (enExample) |
| CN (1) | CN110036107B (enExample) |
| AU (1) | AU2017342273B2 (enExample) |
| CA (1) | CA3039812A1 (enExample) |
| IL (1) | IL265895A (enExample) |
| MA (1) | MA46717A (enExample) |
| MX (1) | MX2019004156A (enExample) |
| RU (1) | RU2019114035A (enExample) |
| SG (1) | SG11201903230QA (enExample) |
| WO (1) | WO2018071565A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| SG11201901757YA (en) | 2016-09-08 | 2019-03-28 | Bluebird Bio Inc | Pd-1 homing endonuclease variants, compositions, and methods of use |
| SG11201903230QA (en) | 2016-10-11 | 2019-05-30 | Bluebird Bio Inc | TCRa HOMING ENDONUCLEASE VARIANTS |
| US11530395B2 (en) | 2016-10-17 | 2022-12-20 | 2Seventy Bio, Inc. | TGFBetaR2 endonuclease variants, compositions, and methods of use |
| CA3122094A1 (en) | 2018-12-10 | 2020-06-18 | Bluebird Bio, Inc. | Pdcd-1 homing endonuclease variants |
| JP2022513750A (ja) * | 2018-12-10 | 2022-02-09 | ２セブンティ バイオ インコーポレイテッド | ホーミングエンドヌクレアーゼバリアント |
| WO2022140150A1 (en) * | 2020-12-21 | 2022-06-30 | 2Seventy Bio, Inc. | Compositions and methods for site-directed mutagenesis |
| EP4355875A1 (en) | 2021-06-14 | 2024-04-24 | 2seventy bio, Inc. | Single stranded rna purification methods |
| US20250043269A1 (en) | 2021-11-03 | 2025-02-06 | The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad | Precise Genome Editing Using Retrons |
| WO2023141602A2 (en) | 2022-01-21 | 2023-07-27 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
| AU2023329392A1 (en) | 2022-08-25 | 2025-02-27 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| AU649074B2 (en) | 1990-10-12 | 1994-05-12 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Modified ribozymes |
| US5652094A (en) | 1992-01-31 | 1997-07-29 | University Of Montreal | Nucleozymes |
| US20020119158A1 (en) * | 1998-12-17 | 2002-08-29 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
| US6692736B2 (en) | 2000-03-24 | 2004-02-17 | Cell Genesys, Inc. | Cell-specific adenovirus vectors comprising an internal ribosome entry site |
| PT1421115E (pt) * | 2001-08-31 | 2005-07-29 | Avidex Ltd | Receptor de celulas t soluvel |
| KR100415267B1 (ko) * | 2002-02-19 | 2004-01-16 | 오광수 | 2단 발효법에 의한 고 순도 멸치액젓 및 그 제조방법 |
| EP1413626A1 (en) * | 2002-10-23 | 2004-04-28 | Vicuron Pharmaceuticals, Inc. | Genes and proteins for the biosynthesis of the glycopeptide antibiotic A40926 |
| US20110239315A1 (en) | 2009-01-12 | 2011-09-29 | Ulla Bonas | Modular dna-binding domains and methods of use |
| US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| WO2011156430A2 (en) | 2010-06-07 | 2011-12-15 | Fred Hutchinson Cancer Research Center | Generation and expression of engineered i-onui endonuclease and its homologues and uses thereof |
| US9034813B2 (en) * | 2010-09-17 | 2015-05-19 | Ecolab Usa Inc. | High performance low viscoelasticity foaming detergent compositions employing extended chain anionic surfactants |
| BR112013030652A2 (pt) * | 2011-06-10 | 2016-12-13 | Basf Plant Science Co Gmbh | polinucleotídeo que codifica um polipeptídeo, molécula de ácido nucleico, vetor, organismo não humano, polipeptídeo e método para introduzir um ácido nucleico de interesse em um genoma de um organismo não humano |
| US8450107B1 (en) * | 2011-11-30 | 2013-05-28 | The Broad Institute Inc. | Nucleotide-specific recognition sequences for designer TAL effectors |
| SG10201806573TA (en) | 2012-05-25 | 2018-09-27 | Cellectis | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
| CA2913872C (en) * | 2013-05-31 | 2022-01-18 | Cellectis | A laglidadg homing endonuclease cleaving the t-cell receptor alpha gene and uses thereof |
| SG11201903230QA (en) | 2016-10-11 | 2019-05-30 | Bluebird Bio Inc | TCRa HOMING ENDONUCLEASE VARIANTS |
-
2017
- 2017-10-11 SG SG11201903230QA patent/SG11201903230QA/en unknown
- 2017-10-11 RU RU2019114035A patent/RU2019114035A/ru not_active Application Discontinuation
- 2017-10-11 MA MA046717A patent/MA46717A/fr unknown
- 2017-10-11 MX MX2019004156A patent/MX2019004156A/es unknown
- 2017-10-11 CA CA3039812A patent/CA3039812A1/en not_active Abandoned
- 2017-10-11 EP EP17859441.2A patent/EP3534916A4/en active Pending
- 2017-10-11 KR KR1020197013234A patent/KR20190065382A/ko not_active Withdrawn
- 2017-10-11 CN CN201780074992.4A patent/CN110036107B/zh active Active
- 2017-10-11 WO PCT/US2017/056178 patent/WO2018071565A1/en not_active Ceased
- 2017-10-11 JP JP2019540313A patent/JP7104710B2/ja active Active
- 2017-10-11 AU AU2017342273A patent/AU2017342273B2/en active Active
- 2017-10-11 US US16/340,257 patent/US11591582B2/en active Active
-
2019
- 2019-04-08 IL IL265895A patent/IL265895A/en unknown
-
2023
- 2023-02-24 US US18/174,165 patent/US12264343B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MA46717A (fr) | 2019-09-11 |
| US12264343B2 (en) | 2025-04-01 |
| MX2019004156A (es) | 2019-09-26 |
| US11591582B2 (en) | 2023-02-28 |
| EP3534916A1 (en) | 2019-09-11 |
| AU2017342273B2 (en) | 2023-07-06 |
| AU2017342273A1 (en) | 2019-05-09 |
| US20230357736A1 (en) | 2023-11-09 |
| KR20190065382A (ko) | 2019-06-11 |
| CA3039812A1 (en) | 2018-04-19 |
| JP7104710B2 (ja) | 2022-07-21 |
| EP3534916A4 (en) | 2020-09-30 |
| US20220186198A1 (en) | 2022-06-16 |
| SG11201903230QA (en) | 2019-05-30 |
| JP2019532674A (ja) | 2019-11-14 |
| CN110036107B (zh) | 2024-12-27 |
| IL265895A (en) | 2019-06-30 |
| WO2018071565A1 (en) | 2018-04-19 |
| CN110036107A (zh) | 2019-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019532674A5 (enExample) | ||
| JP7026161B2 (ja) | 免疫調節性融合タンパク質およびその使用 | |
| US12297274B2 (en) | Method of cell therapy | |
| US12209125B2 (en) | Targeted gene integration of NK inhibitors genes for improved immune cells therapy | |
| Rajsbaum et al. | Type I interferon‐dependent and‐independent expression of tripartite motif proteins in immune cells | |
| Marshall et al. | NKG2C/E marks the unique cytotoxic CD4 T cell subset, ThCTL, generated by influenza infection | |
| US11873511B2 (en) | Targeted gene insertion for improved immune cells therapy | |
| JP6069755B2 (ja) | 高親和性ｔ細胞受容体およびその用途 | |
| KR102308597B1 (ko) | 다중 종양에 대항하여 항체-의존성 세포 세포독성을 촉발시키는 키메라 수용체 | |
| KR102186180B1 (ko) | 면역 기능 제어 인자를 발현하는 면역 담당 세포 및 발현 벡터 | |
| US20220119477A1 (en) | Tcr and peptides | |
| JP2020521456A5 (enExample) | ||
| HRP20211113T1 (hr) | Pripravci i metode za ciljanu dostavu citokina | |
| EA201591213A1 (ru) | Вакцины против вируса гепатита b | |
| JP2022532557A5 (enExample) | ||
| KR20170076775A (ko) | T 세포가 아닌 종양을 표적화하는 서바이빈 특이적인 t-세포 수용체 | |
| Claus et al. | Regulation of NK cell activity by 2B4, NTB-A and CRACC | |
| CN107974433B (zh) | 一种增强型抗肿瘤nk细胞及其制备方法和应用 | |
| US20200223899A1 (en) | Braf-specific tcrs and uses thereof | |
| CN114014941A (zh) | 靶向IL13Rα2的嵌合抗原受体及其用途 | |
| Sadrabadi et al. | A comprehensive review on T cells, B cells, natural killer cells, and dendritic cells exhaustion: from main concepts to clinical use | |
| Karunakaran | Evolution of Vγ9Vδ2 T-cells | |
| Tao et al. | A novel HLA allele, HLA‐C* 01: 02: 18, was identified by polymerase chain reaction sequence‐based typing in a Chinese leukemia patient | |
| Ghobadinezhad et al. | Adoptive cell transfer for solid tumors | |
| Vila De Mucha | Transcriptional regulation of tumour infiltrating cytotoxic CD4+ T cell differentiation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20201012 |